MSTN and sarcopenia: Various negative regulators increase protein degradation in muscular dystrophy and sarcopenia, and, of these, myostatin (MSTN) effectively inhibits muscle growth, and thus is regarded as a potential curative target for the treatment of muscle wasting associated diseases [18].